SciSparc (SPRC) Non-Current Assets (2016 - 2025)
SciSparc (SPRC) posted Non-Current Assets of $2.2 million for Q4 2025, down 8.54% sequentially from $2.4 million in Q2 2025, and down 23.14% YoY from $2.8 million in Q4 2024.
SciSparc (SPRC) Non-Current Assets (2016 - 2025) Analysis & Trends
SciSparc has reported Non-Current Assets for 10 years, with the latest figure at $2.2 million in Q4 2025.
- Quarterly Non-Current Assets fell 23.14% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.5 million (down 30.59% YoY) and the FY2025 annual result came in at $2.2 million, down 23.14% from the prior year.
- Non-Current Assets slipped to $2.2 million in Q4 2025 per SPRC's latest filing, from $2.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $7.1 million in Q2 2024 and troughed at $10000.0 in Q2 2021.
- A 5-year average of $3.2 million and a median of $2.6 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2022: Non-Current Assets plunged 98.72% in 2021, then soared 7280.0% in 2022.
- Over 5 years, Non-Current Assets stood at $92000.0 in 2021, then surged by 6525.0% to $6.1 million in 2022, then retreated by 22.28% to $4.7 million in 2023, then sank by 39.96% to $2.8 million in 2024, then declined by 23.14% to $2.2 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $2.2 million, $2.4 million, and $2.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 18.06 Bn |
| 10 | SciSparc | 807,202.50 | 807,202.50 | - | 2.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.19 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Jun 30, 2024 | 7.13 Mn |
| Dec 31, 2023 | 4.74 Mn |
| Jun 30, 2023 | 6.25 Mn |
| Dec 31, 2022 | 6.10 Mn |
| Jun 30, 2022 | 738,000.00 |
| Dec 31, 2021 | 92,000.00 |
| Jun 30, 2021 | 10,000.00 |
| Dec 31, 2020 | 11,000.00 |
| Jun 30, 2020 | 783,000.00 |
| Dec 31, 2019 | 199,000.00 |
| Jun 30, 2019 | 233,000.00 |
| Dec 31, 2018 | 2.13 Mn |
| Jun 30, 2018 | 106,000.00 |
| Dec 31, 2017 | 69,000.00 |
| Sep 30, 2017 | 31,000.00 |
| Jun 30, 2017 | 17,000.00 |
| Mar 31, 2017 | 11,000.00 |